

# VERTEX PHARMACEUTICALS INC.

ISIN: **US92532F1003** WKN: **92532F100**

## Overview

2024/05/17 17:35:47	
<b>Price</b>	407.60 EUR
<b>Difference</b>	<span style="color: green;">▲</span> 1.37% (5.50)

<b>General attributes</b>	
ISIN	US92532F1003
Symbol	VRTX
Exchange	Xetra
Currency	EUR
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	105,718 EUR
Benchmark	S&P 500

<b>Market data</b>	
Bid (Bid size)	-
Ask (Ask size)	-
Open	406.55 EUR
High	408.00 EUR
Low	405.30 EUR
Close (prev. day)	402.10 EUR
VWAP	407.09302 EUR
Volume (pcs)	86
Trading volume	35,010.00
Number of trades	12
Last size	1

<b>Futures and Options</b>	
Related Futures	-
Related Options	-

<b>PDF Downloads</b>	
Company report: VERTEX PHARMACEUTICALS INC.	



Information about previous performance does not guarantee future performance.  
**Source:** FactSet

### Recent research

on instrument	on sector	on market	
Date		Headline	Download
2024/04/26		Global Equity Ratings	
2024/04/03		Global Equity Ratings	
2024/03/13		Global Equity Ratings	
2024/02/22		Global Equity Ratings	
2024/02/14		Global Equity Ratings	

## Details

2024/05/17 17:35:47

**Price**

407.60 EUR

**Difference** ▲ 1.37% (5.50)

**General attributes**

**ISIN** US92532F1003

**Symbol** VRTX

**Exchange** Xetra

**Currency** EUR

**Sector** Chemical / Pharmaceutical / Health

**Security type** Stock

**Market cap (m)** 105,718 EUR

**Benchmark** S&P 500

**Market data**

**Bid (Bid size)** -

**Ask (Ask size)** -

**Open** 406.55 EUR

**High** 408.00 EUR

**Low** 405.30 EUR

**Close (prev. day)** 402.10 EUR

**VWAP** 407.09302 EUR

**Volume (pcs)** 86

**Trading volume** 35,010.00

**Number of trades** 12

**Last size** 1

**Performance and Risk**

	6m	1Y	3Y
<b>Perf (%)</b>	+28.58%	+29.52%	+128.22%
<b>Perf (abs.)</b>	+90.60	+92.90	+229.00
<b>Beta</b>	0.74	0.66	0.61
<b>Volatility</b>	23.69	22.32	26.72

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

**Price data**

**Ø price 5 days | Ø volume 5 days (pcs.)** 399.59 EUR (95)

**Ø price 30 days | Ø volume 30 days (pcs.)** 379.13 EUR (167)

**Ø price 100 days | Ø volume 100 days (pcs.)** 385.45 EUR (152)

**Ø price 250 days | Ø volume 250 days (pcs.)** 350.98 EUR (108)

**YTD High | date** 420.00 EUR (2024/01/31)

**YTD Low | date** 353.40 EUR (2024/04/11)

**52 Weeks High | date** 420.00 EUR (2024/01/31)

**52 Weeks Low | date** 298.40 EUR (2023/06/01)

**All listings for VERTEX PHARMACEUTICALS INC.**

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/05/17	17:35	407.60 EUR	0.04	12
Vienna Stock Exchange	2024/05/17	17:32	407.00 EUR	0.00	3
Tradegate	2024/05/17	22:26	409.55 EUR	0.22	34
Stuttgart	2024/05/17	21:59	409.25 EUR	0.00	4
Nasdaq	2024/	22:00	445.21 USD	614.18	31,283

	05/17					
Munich	2024/ 05/17	10:26	406.35 EUR	0.01		2
London Stock Exchange	2024/ 05/15	15:30	430.93 USD	0.00		1
Hanover	2024/ 05/17	08:26	405.05 EUR	0.00		3
Hamburg	2024/ 05/17	08:10	404.70 EUR	0.00		3
Frankfurt	2024/ 05/17	17:15	407.15 EUR	0.04		6
Euronext Milan MTF Trading After Hours	2024/ 04/29	20:01	371.75 EUR	0.00		1
Euronext Milan MTF Global Equity Market	2024/ 05/17	17:44	406.25 EUR	0.02		6
Duesseldorf	2024/ 05/17	19:30	407.10 EUR	0.00		7
Berlin	2024/ 05/17	08:08	405.05 EUR	0.00		2

## Company profile

### Company Logo



### Contact Details

VERTEX PHARMACEUTICALS INC.

--

50 Northern Avenue - 02210 Boston

Telefon: +1-617-341-6100

Fax: +

E-mail: [mediainfo@vrtx.com](mailto:mediainfo@vrtx.com)

### PDF Downloads

Company report: VERTEX PHARMACEUTICALS INC.



### Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

### Members of Management Board

Jeffrey Leiden Chairman of Board of Directors

Alan Garber Member of Board of Directors

Sangeeta Bhatia Member of Board of Directors

Bruce Sachs Member of Board of Directors

Diana McKenzie Member of Board of Directors

Lloyd Carney Member of Board of Directors

Michel Lagarde Member of Board of Directors

Nancy Thornberry Member of Board of Directors

Suketu Upadhyay Member of Board of Directors

Reshma Kewalramani Chairman of Managing Board

David Altshuler Member of Executive Committee

Amit K. Sachdev Member of Executive Committee

Bastiano Sanna Member of Executive Committee

Carmen Bozic Member of Executive Committee

Charles F. Wagner Member of Executive Committee

E. Morrey Atkinson Member of Executive Committee

Jonathan Biller Member of Executive Committee

Nia Tatsis Member of Executive Committee

Stuart A. Arbuckle Member of Executive Committee